GATBIO NEXT
Financiado
GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonst...
GATBIO NEXT: advancing GRT's 1st oral biologic - GB-AF-004 - to clinical demonstration and out-licensing
GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary marke...
GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary markets. Specifically, we are developing a game-changer next generation of accessible and non-invasive (oral, topic, inhaled) biopharmaceuticals through proprietary and sustainable microalgae biofactories.
Our first candidate for the biopharmaceutical Market, GB-AF-004, will enter pre-clinical demonstration in 2023. GB-AF-004 is an anti-inflammatory biologic for the oral treatment of Inflammatory Bowel Diseases and Disorders (IBDs). The term IBDs includes a range of chronic and painful autoimmune diseases affecting localy the intestine, affecting patients from their youth and throughout life and of unknown causess. More than 6 million people are affected by IBDs globally and their global treatment market is estimated by 2029 at 37 billion euros per year. GB-AF-004 has the potential to be a game-changer in the treatment of this high prevalence and chronic inflammatory intestinal diseases.
GATBIO has been recently granted a Seal of Excellence from the EIC accelerator Program supporting disruptive European SMEs for their acceleration to the market. The related funding will allow us to enter the preclinical development of GB-AF-004 early in 2023. In this frame, additional support related not to scientific development per se but to reinforcing our strategic business management and vision could be key to success in our next steps and culminate GB-AF-004 out-licensing. Specifically, to access Expert mentoring and Biomed advice related to i) clinical positioning in the IBD market and ii) out-licensing strategy, would be key to success in the arrival of our 1st candidate to the regulated market and would translate into GATBIO’s consolidation and exponential growth based on innovation out-licensing.
ver más
Duración del proyecto: 12 meses
Fecha Inicio: 2023-05-31
Fecha Fin: 2024-05-31
Fecha Fin: 2024-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIE-2022-SCALEUP-02-02:
Women TechEU
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
75K€
Líder del proyecto
GAT BIOSCIENCES
La investigacion y desarrollo de productos basados en biotecnologia asi como la prestacion de servicios de investigacion y desarrollo de pro...
Perfil tecnológico
TRL
3-4
1M
Perfil tecnológico
TRL
3-4
1M